Myocardial infarction in a patient with moderate haemophilia A

Czubak, E; Serwicka, Aleksandra; Dziekoński, Andrzej; Fitas, Grzegorz

doi:10.5114/pwki.2011.21198

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional data is provided by recently published coronary angiography reports describing significant or critical stenosis of one or more vessels [51][52][53][54][55] or acute thrombotic occlusions [53,56,57]. Intrastent thrombosis as a cause for AMI was also reported [58].…”

Section: Acute Myocardial Infarction In Patients With Hemophiliamentioning

confidence: 99%

Current Therapeutic Approach to Acute Myocardial Infarction in Patients with Congenital Hemophilia

Bădescu

Ciocoiu

Rezuş

et al. 2021

Life

View full text Add to dashboard Cite

Advances in the treatment of hemophilia have made the life expectancy of hemophiliacs similar to that of the general population. Physicians have begun to face age-related diseases not previously encountered in individuals with hemophilia. Treatment of acute myocardial infarction (AMI) is particularly challenging because the therapeutic strategies influence both the patient’s thrombotic and hemorrhagic risk. As progress has been made in the treatment of AMI over the last decade, we performed an in-depth analysis of the available literature, highlighting the latest advances in the therapy of AMI in hemophiliacs. It is generally accepted that after the optimal substitution therapy has been provided, patients with hemophilia should be treated in the same way as those in the general population. New-generation stents that allow short dual antiplatelet therapy and potent P2Y12 receptor inhibitors have begun to be successfully used. At a time when specific recommendations and relevant data are scarce, our study provides up-to-date information to physicians involved in the treatment of AMI in hemophiliacs.

show abstract